OncoTricks

Medullary thyroid carcinoma, Oct 18, 2026

A neuroendocrine tumor in a neck node that stains for calcitonin

If you remember one thingCalcitonin-positive neuroendocrine tumor in a cervical or mediastinal node is medullary thyroid carcinoma until the serum calcitonin says otherwise. The label on the chart is not evidence.

From the pathology comment to the diagnosis

Node biopsy: neuroendocrine, TTF-1+ calcitonin positive, Ki-67 low, chromogranin+ 1 Serum calcitonin and CEA before anyone writes a diagnosis 2 CALCITONIN over 100 pg/mL Medullary carcinoma ultrasound, RET, metanephrines 3 20 to 100 Indeterminate false positives first, then repeat
1
The slide. Medullary carcinoma is neuroendocrine, often TTF-1 positive, and stains for calcitonin, chromogranin, synaptophysin and CEA; thyroglobulin is negative. In a node it is routinely filed as "neuroendocrine tumor" or "atypical carcinoid", and the diagnosis then travels through every subsequent note. Read the pathologist's comment, not the line on the problem list.
2
The blood. Basal calcitonin above 100 pg/mL had a positive predictive value of 100% in 5,817 nodules; 20 to 100 is the gray zone (Costante 2007). CEA is high at diagnosis in about half to two thirds, rising with stage (Kim 2021), so a normal CEA excludes nothing. On a thyroid nodule, cytology alone finds medullary carcinoma in about half; calcitonin measured in the needle washout finds 98% (Trimboli 2022).
3
False positives for calcitonin. Proton pump inhibitors, kidney failure, autoimmune thyroiditis, hyperparathyroidism, C-cell hyperplasia, other neuroendocrine tumors (lung above all), heterophile antibodies, smoking, sepsis on older assays. Mnemonic: PRICHS: PPI, Renal, Immune thyroiditis, C-cell hyperplasia and Carcinoids, Habit of smoking, Sepsis. A lung neuroendocrine tumor can reach 1,000 to 2,000 pg/mL (Llewellyn 2021): the thyroid ultrasound and the needle washout settle the origin, not the serum number alone.

The scan reads "thymic" or "mediastinal" because that is where the node is, not where the tumor started.A medullary carcinoma that presents as a mediastinal mass with a small calcified thyroid nodule is still a thyroid cancer, and the thyroid is still the primary to examine, image and, if the disease is confined to the neck, resect.

RET, the families, and why the adrenal comes first

If you remember one thingEvery medullary carcinoma gets a germline RET test, and every patient gets plasma metanephrines before anyone operates on anything.

The receptor, drawn

inside the cell outside Cysteine-rich domain codons 609, 611, 618, 620, 630, 634 a lost cysteine pairs two receptors without a ligand 634 kinase Tyrosine kinase domain codon 918: the receptor switches itself on, alone 918 MEN2A Medullary carcinoma, nearly all Pheochromocytoma 30 to 50% Hyperparathyroidism 10 to 25% 634 is the king of 2A MEN2B Medullary carcinoma in childhood Pheochromocytoma about 50% Mucosal neuromas, marfanoid, gut No hyperparathyroidism M918T, 3 in 4 are de novo 1 2 3 sporadic: 1 in 2 has a somatic RET, mostly 918; RAS in the rest
1
MEN2A, the three P. Parafollicular C cells (medullary carcinoma), Pheochromocytoma, Parathyroid. Cysteine codons of the extracellular domain; 634 is the commonest and carries the most pheochromocytoma and hyperparathyroidism. Variants: cutaneous lichen amyloidosis (itchy interscapular plaques, almost only 634) and Hirschsprung disease (exon 10 codons 609 to 620). "Familial MTC" is MEN2A with low penetrance of the other two.
2
MEN2B, three M and a P, no parathyroid. Mucosal neuromas (lips, tongue), Marfanoid habitus, M918T, Pheochromocytoma. Chronic constipation from gut ganglioneuromatosis and tearless crying are the early clues; most cases are de novo, so no family history is expected. Thyroidectomy in the first year of life.
3
Sporadic, 3 in 4. Somatic RET in about half (M918T first, associated with worse outcome in the Pisa series, not in every series), RAS in 20 to 80% of the rest, the two mutually exclusive. Germline RET is still sent to everyone: 1 to 7% of "sporadic" tumors turn out hereditary (7.3% in 481 Pisa patients, Elisei 2007), and a positive test changes screening for the children.

Risk by codon, and when the carrier's thyroid comes out

ATA riskRET mutationProphylactic thyroidectomy
HighestM918T (MEN2B)In the first year of life
HighCodon 634, A883FAt or before age 5; earlier if calcitonin rises
Moderate609, 611, 618, 620, 630, 768, 790, 804, 891 and othersWhen calcitonin rises; annual calcitonin and ultrasound from age 5

Calcitonin, not the codon alone, times the operation in carriers.Node metastases are unlikely below 40 pg/mL. The codon sets the ceiling of risk; the calcitonin tells you where the patient is under it (Wells 2015).

Before any scalpel

1. Is there a medullary carcinoma, hereditary or not?
yes
Plasma free metanephrines firstOr 24-hour urine fractionated metanephrines. Positive: adrenal imaging and adrenalectomy BEFORE thyroidectomy or any procedure under anesthesia. An unrecognized pheochromocytoma under anesthesia causes hypertensive crisis and has killed patients (Wells 2015).
then
2. Calcium and PTH, germline RET, neck ultrasound
then
Total thyroidectomy with central neck dissectionBilateral and multifocal disease is the rule in hereditary cases; the C cell does not take iodine, so surgery is the only cure. Lateral neck dissection when nodes are seen or the calcitonin predicts them.
and
3. Cured means calcitonin undetectable at 3 monthsThen 10-year survival 97.7% in 899 patients (Modigliani 1998). Detectable calcitonin after surgery is persistent disease, which is common and often indolent: the next tab decides what to do with it.

Pheo first. Always. In both syndromes, before every operation.

Calcitonin and CEA as the clock of the disease

If you remember one thingThe doubling time of calcitonin and CEA predicts survival better than the stage. Below 6 months is a different disease from above 2 years.

Doubling time against survival

Calcitonin doubling time5-year survival10-year survival
Under 6 months25%8%
6 to 24 months92%37%
Over 24 months100%100%

Four values over time, calcitonin and CEA both; the ATA website has the calculator.Barbet 2005, 65 patients; confirmed in the meta-analysis of Meijer 2010 (doubling time under 1 year against over 1 year). In the meta-analysis the CEA doubling time predicted even better than the calcitonin one. Discordance, CEA climbing while calcitonin stalls, means a tumor losing calcitonin and keeping CEA: dedifferentiation, and the worse of the two clocks is the one to believe.

What the number tells you where

Before surgery, nodesUnder 20 pg/mL: node metastases nearly never.
Over 20: central and ipsilateral lateral neck.
Over 50: contralateral central.
Over 200: contralateral lateral.
Over 500: upper mediastinum (Machens 2010; with current assays the thresholds are higher, 242 pg/mL for the central neck, Du 2025).
After surgery, distanceUnder 150 pg/mL: disease outside the neck is unlikely; neck ultrasound and markers every 6 to 12 months.
150 or more: CT or MRI of neck, chest and liver, bone scan and MRI of spine and pelvis.
Recurrence imaging: F-DOPA PET is the most accurate; DOTATATE PET for bone and for lutetium candidates; an FDG-avid tumor is a fast one: avidity tracks short doubling time and poor survival. Neither PET is for initial staging.

Rising markers alone never start systemic therapy.Treatment is for structural progression by RECIST or for symptoms. A calcitonin in the thousands with stable scans and a doubling time of 3 years is watched, not treated (Wells 2015; NCCN 2026).

Three things the C cell does not do

1
It does not take iodine. No radioiodine, except for the rare tumor mixed with a follicular-cell cancer. Levothyroxine after thyroidectomy is replacement to a normal TSH, not suppression: TSH does not drive C cells.
2
It does not make thyroglobulin. Thyroglobulin is the marker of the follicular cancers and is useless here. Calcitonin and CEA are the pair.
3
It does not respond to chemotherapy in any durable way. Dacarbazine-based regimens give responses in a minority and are the last line, after the kinase inhibitors.

Unresectable or metastatic: what cannot be cut

If you remember one thingThe RET result chooses the first drug. RET-mutated: selpercatinib. RET wild-type: cabozantinib or vandetanib. Nobody starts any of them for a number.

The algorithm

Unresectable or metastatic, and growing by RECIST or symptoms; RET result on the block RET Mutated Selpercatinib response 69%, PFS HR 0.28 germline or somatic, either 1 Wild-type Cabozantinib or vandetanib PFS HR 0.28 and 0.46 against placebo 2 Progression: trial, then the other inhibitor chemotherapy last; lutetium if somatostatin-avid 3
1
Selpercatinib, LIBRETTO-531. Phase 3, first line, RET-mutated: selpercatinib against cabozantinib or vandetanib. Progression-free survival not reached against 16.8 months (HR 0.28); response 69.4% against 38.8%; stopped for toxicity 4.7% against 26.8% (Hadoux 2023). Watch blood pressure, liver tests every 2 weeks for 3 months, and the QT interval. Pralsetinib, the other selective inhibitor, lost its US thyroid indication in June 2023; selpercatinib stands alone.
2
Cabozantinib, EXAM; vandetanib, ZETA. Multikinase inhibitors, approved before the RET result mattered. EXAM: progression-free survival 11.2 against 4.0 months (HR 0.28), response 28% against 0, no overall survival benefit in all comers; 44.3 against 18.9 months in the M918T subgroup, an exploratory analysis (Elisei 2013; Schlumberger 2017). ZETA: HR 0.46, predicted medians 30.5 against 19.3 months, response 45% against 13% (Wells 2012); QT prolongation with a boxed warning (the REMS program was removed in September 2025). Cabozantinib: diarrhea, hand-foot skin reaction and hypertension, dose reduced in 79%; vandetanib, about a third.
3
After the inhibitor. Clinical trial first; then the kinase inhibitor not yet used; dacarbazine-based chemotherapy last. Lutetium-DOTATATE for somatostatin-receptor-avid disease is an option without phase 3 data. Resistance to selpercatinib: on-target solvent-front RET mutations (G810) in some, bypass through MET amplification in others; the next generation of inhibitors targets the first.

Decide in clinic

1. Growing on scans, or symptomatic?No: watch. Markers every 6 months, imaging by doubling time. Most metastatic medullary carcinoma is indolent for years.
yes
Treat. RET result in hand firstGermline and somatic. Selpercatinib if either is mutated. Cabozantinib or vandetanib if wild-type.
then
2. Unresectable neck or mediastinal disease?
yes
Systemic therapy, not surgeryEncased great vessels mean no operation. Radiation lowers locoregional recurrence and does not change survival (Rowell 2019): consider it after surgery with residual disease, extrathyroidal extension or extensive nodes, and for airway or local symptoms.
then
3. Diarrhea, flushing?
yes
Loperamide, then octreotideSecretory diarrhea from calcitonin and other peptides marks high tumor burden, usually liver. Telotristat is off-label here. The kinase inhibitor itself causes diarrhea: separate the two.
and
4. On a kinase inhibitorBlood pressure every visit. ECG before and on treatment. Liver tests every 2 weeks early. Dose reduction, not discontinuation, keeps most patients on drug.

The ultrasound, the metanephrines and the RET result: three tests before the first prescription.

Mnemonics, and the questions you will be asked

If you remember one thingPheo first. 634 rules 2A. 918 is the worst. CEA up and calcitonin down is dedifferentiation. 150 sends you to the body scan. Doubling time beats stage.

Eight to carry

1
MEN2A, three P: Parafollicular, Pheo, Parathyroid.
2
MEN2B, three M and a P, no parathyroid: Mucosal neuromas, Marfanoid, M918T, Pheo.
3
634 is the king of 2A: commonest codon, most pheochromocytoma and hyperparathyroidism.
4
918 is the worst: germline in MEN2B (thyroid out in year one), somatic in the sporadic tumors that behave worst in most series.
5
Pheo first: metanephrines before any operation, in every patient.
6
CEA up, calcitonin down: the tumor is dedifferentiating; the worse clock wins.
7
150 is the body number: below it, disease outside the neck is unlikely; above it, image the chest and liver.
8
PRICHS for a calcitonin that is high without cancer: PPI, Renal, Immune thyroiditis, C-cell hyperplasia and Carcinoids, Habit of smoking, Sepsis.

Questions

Q
Which marker, and what number closes it? Calcitonin; basal over 100 pg/mL is medullary carcinoma until proven otherwise, once a lung neuroendocrine tumor is off the table. CEA is the companion, not the screen.
Q
Does every patient need genetic testing? Yes. Germline RET in all; 1 to 7% of apparently sporadic tumors are hereditary. Somatic RET on the tumor when the disease is advanced and the germline is negative.
Q
What do you check before surgery? Metanephrines in everyone; calcium and PTH in MEN2A; neck ultrasound; calcitonin to plan the extent of node dissection.
Q
Does MEN2B have hyperparathyroidism? No. At the bedside what separates it from 2A are the mucosal neuromas, the marfanoid habitus, the gut and the tearless crying.
Q
When do you start systemic therapy? Structural progression by RECIST or symptoms. Never for a rising calcitonin alone.
Q
First line in RET-mutated disease? Selpercatinib (LIBRETTO-531: response 69%, PFS HR 0.28, fewer discontinuations than cabozantinib or vandetanib).
Q
Is there any role for radioiodine or TSH suppression? None. C cells take no iodine and have no TSH receptor that matters; levothyroxine is replacement only.
Q
Bilateral adrenal nodules on the staging scan? Pheochromocytoma until the metanephrines say otherwise, even when the report says "metastases". Nobody is sedated before that result.
Q
A patient cured by surgery: how do you follow? Calcitonin and CEA at 3 months; if undetectable, every 6 months for a year, then yearly. MEN2 carriers get yearly metanephrines from age 11 (high and highest risk) or 16 (moderate), and in 2A calcium on the same schedule (Wells 2015).
Q
What grades the tumor? The international grading system (mitoses, Ki-67, necrosis): 10-year survival 91% low grade against 47% high grade (Xu 2022). Ask the pathologist to report it.
Sources

Retrieved from PubMed, read on Oct 20, 2026.

  1. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015. doi:10.1089/thy.2014.0335
  2. Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer (LIBRETTO-531). N Engl J Med 2023. doi:10.1056/NEJMoa2309719
  3. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer (EXAM). J Clin Oncol 2013. doi:10.1200/JCO.2012.48.4659
  4. Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017. doi:10.1093/annonc/mdx479
  5. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer (ZETA). J Clin Oncol 2012. doi:10.1200/JCO.2011.35.5040
  6. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005. doi:10.1210/jc.2005-0044
  7. Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf) 2010. doi:10.1111/j.1365-2265.2009.03666.x
  8. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010. doi:10.1210/jc.2009-2368
  9. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007. doi:10.1210/jc.2006-1590
  10. Xu B, Fuchs TL, Ahmadi S, et al. International Medullary Thyroid Carcinoma Grading System: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 2022. doi:10.1200/JCO.21.01329
  11. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008. doi:10.1210/jc.2007-1714
  12. Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020. doi:10.1007/s00259-019-04458-6
  13. Saba NF, Ismaila N, Adkins D, et al. Systemic treatment of thyroid cancer: ASCO guideline. J Clin Oncol 2026. doi:10.1200/JCO-26-00235
  14. Du Y, Shen C, Song K, et al. Updated thresholds of basal calcitonin level and extent of lymph node metastasis in initially treated medullary thyroid cancer. JAMA Otolaryngol Head Neck Surg 2025. doi:10.1001/jamaoto.2025.0542
  15. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 1998. doi:10.1046/j.1365-2265.1998.00392.x
  16. Trimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine 2022. doi:10.1007/s12020-021-02892-x
  17. Kim J, et al. Serum carcinoembryonic antigen as a biomarker for medullary thyroid carcinoma. Int J Thyroidol 2021. doi:10.11106/ijt.2021.14.1.59
  18. Llewellyn D, et al. Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review. Endocr Connect 2021. doi:10.1530/EC-21-0170
  19. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007. doi:10.1210/jc.2007-1005
  20. Rowell NP. The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: a systematic review. Radiother Oncol 2019. doi:10.1016/j.radonc.2019.03.033
  21. Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol 2020. doi:10.1016/j.jtho.2020.01.006
  22. Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 2020. doi:10.1016/j.annonc.2020.09.015
  23. Verbeek HH, Plukker JT, Koopmans KP, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012. doi:10.2967/jnumed.112.105940